INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate

PLYMOUTH MEETING, Pa., Aug. 26, 2021. INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials